Richard Margolin

North Hertfordshire College — United Kingdom

Medicine · Health Sciences

28h-index13.3kcitations90works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(30), Medical Imaging Techniques and Applications(21), Medical Image Segmentation Techniques(15), Dementia and Cognitive Impairment Research(12), Advanced MRI Techniques and Applications(9)

Publications90 total

The antibody TBL‐100 binds with picomolar affinity and high specificity to the free carboxy terminus of tauC3 in tau oligomers involved in spreading of pathology in AD
Alzheimer s & Dementia·2025Open Access
AlphaFold 2 predicts a markedly different MTBR conformation for 3‐repeat and 4‐repeat tau isoforms
Alzheimer s & Dementia·2024· 1 citedOpen Access
APNmAb005, an anti‐tau antibody targeting synaptic tau oligomers, in Phase 1 for treatment of Alzheimer’s Disease and primary tauopathies
Alzheimer s & Dementia·2023· 7 citedOpen Access
The AI‐based AlphaFold 2 algorithm predicts an open structure for tauC3
Alzheimer s & Dementia·2023· 1 citedOpen Access
AlphaFold 2 predicts opening of the tau hairpin conformation by <i>Mapt</i> mutations and the extent of opening reflects their location
Alzheimer s & Dementia·2023· 1 citedOpen Access
PROGRESS IN DEVELOPING A LIGHT‐STABLE 4R TAU PET IMAGING AGENT: APN‐1701 FIH
Alzheimer s & Dementia·2022
PROGRESS TOWARDS AN A‐SYNUCLEIN PET TRACER
Alzheimer s & Dementia·2022
IN‐VIVO EVALUATION OF APN‐1808, A TAU SMALL MOLECULE THERAPEUTIC
Alzheimer s & Dementia·2022
PROGRESS IN DEVELOPING A LIGHT‐STABLE 4R TAU PET IMAGING AGENT: APN‐1701 FIH
Alzheimer s & Dementia·2022
The APP intracellular domain promotes <i>LRRK2</i> expression to enable feed-forward neurodegenerative mechanisms in Parkinson’s disease
Science Signaling·2022· 10 cited
The tau oligomer antibody APNmAb005 detects early-stage pathological tau enriched at synapses and rescues neuronal loss in long-term treatments
2022· 14 citedOpen Access
Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease
Acta Neuropathologica Communications·2019· 266 citedOpen Access
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects
Journal of Alzheimer s Disease·2019· 24 citedOpen Access
Additional file 1: of Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimerâ s disease
Figshare·2019Open Access
F4‐06‐01: TIMING AND TRAJECTORY OF ESTABLISHED MECHANISMS: AMYLOID β AND TAU DEPOSITION, AND NEURODEGENERATION
Alzheimer s & Dementia·2018
The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable
Alzheimer s & Dementia·2018· 137 citedOpen Access
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer’s disease
Journal of Alzheimer s Disease·2016· 30 cited
P2‐015: Pooled Amyloid Pet Baseline Data from The Bapineuzumab IV Phase III Trials
Alzheimer s & Dementia·2016
P3‐012: Advancing Therapeutics for Neuroinflammation in Alzheimer's Disease: Clinical Development Considerations
Alzheimer s & Dementia·2016
The roles of inflammation and immune mechanisms in Alzheimer's disease
Alzheimer s & Dementia Translational Research & Clinical Interventions·2016· 229 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Benoît M. Dawant(9), Gordon R. Bernard(6), Joseph Francis(6), Theodore Speroff(6), Shiva Gautam(6), Robert S. Dittus(6), Robert Kessler(6), J. Michael Fitzpatrick(6), Brenda Truman(5), Alex Zijdenbos(5), Ronald G. Manning(5), Rodney A. Brooks(5), Monte S. Buchsbaum(5), E. Wesley Ely(4), Sharon K. Inouye(4), Lisa May(4), Mark E. Schmidt(4), William H. Theodore(4), Roger J. Porter(4), Edythe D. London(4)